

This copy is for your personal, non-commercial use only.

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

The following resources related to this article are available online at www.sciencemag.org (this information is current as of January 30, 2012):

Updated information and services, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/content/332/6027/358.full.html>

Supporting Online Material can be found at:

<http://www.sciencemag.org/content/suppl/2011/04/12/332.6027.358.DC1.html>

A list of selected additional articles on the Science Web sites **related to this article** can be found at:

<http://www.sciencemag.org/content/332/6027/358.full.html#related>

This article **cites 27 articles**, 9 of which can be accessed free:

<http://www.sciencemag.org/content/332/6027/358.full.html#ref-list-1>

This article has been **cited by 2** articles hosted by HighWire Press; see:

<http://www.sciencemag.org/content/332/6027/358.full.html#related-urls>

This article appears in the following **subject collections**:

Medicine, Diseases

<http://www.sciencemag.org/cgi/collection/medicine>

6. J. Y. Roignant, J. E. Treisman, *Int. J. Dev. Biol.* **53**, 795 (2009).
7. R. Reifegerste, K. Moses, *Bioessays* **21**, 275 (1999).
8. J. P. Kumar, K. Moses, *Cell* **104**, 687 (2001).
9. C. Jones, K. Moses, *Semin. Cell Dev. Biol.* **15**, 75 (2004).
10. A. Schlesinger, A. Kiger, N. Perrimon, B. Z. Shilo, *Dev. Cell* **7**, 535 (2004).
11. D. Alvarado, A. H. Rice, J. B. Duffy, *Genetics* **167**, 187 (2004).
12. M. Freeman, *Cell* **87**, 651 (1996).
13. A. Guha, L. Lin, T. B. Kornberg, *Dev. Biol.* **335**, 317 (2009).
14. M. Sato, T. B. Kornberg, *Dev. Cell* **3**, 195 (2002).
15. R. Schweitzer, M. Shaharabany, R. Seger, B. Z. Shilo, *Genes Dev.* **9**, 1518 (1995).
16. E. Ruberte, T. Marty, D. Nellen, M. Affolter, K. Basler, *Cell* **80**, 889 (1995).
17. M. Cohen, M. Georgiou, N. L. Stevenson, M. Miodownik, B. Baum, *Dev. Cell* **19**, 78 (2010).

Acknowledgments: We thank H. Li and K. Kechris for help with data analysis; S. Liu for technical help; the Bloomington *Drosophila* Stock Center, I. Guerrero, E. Bier, M. Krasnow, J. Duffy, M. Sato, and K. Wharton for fly stocks; and T. Wunderlich for hCre*PR*. This work was supported in part by a Herbert Boyer Postdoctoral

Fellowship (to S.R.) and by grants from the National Institute of General Medical Studies and the National Heart, Lung, and Blood Institute to T.B.K.

Supporting Online Material

www.sciencemag.org/cgi/content/full/332/6027/354/DC1
Materials and Methods

Figs. S1 to S4
Tables S1 to S5
References

12 October 2010; accepted 1 March 2011
10.1126/science.1198949

Noncanonical TGF β Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice

Tammy M. Holm,^{1*} Jennifer P. Habashi,^{1,2*} Jefferson J. Doyle,^{1*} Djahida Bedja,³
YiChun Chen,¹ Christel van Erp,¹ Mark E. Lindsay,^{1,2} David Kim,¹ Florian Schoenhoff,¹
Ronald D. Cohn,^{1,2} Bart L. Loeys,⁴ Craig J. Thomas,⁵ Samarjit Patnaik,⁵ Juan J. Marugan,⁵
Daniel P. Judge,⁶ Harry C. Dietz^{1,2,6†}

Transforming growth factor- β (TGF β) signaling drives aneurysm progression in multiple disorders, including Marfan syndrome (MFS), and therapies that inhibit this signaling cascade are in clinical trials. TGF β can stimulate multiple intracellular signaling pathways, but it is unclear which of these pathways drives aortic disease and, when inhibited, which result in disease amelioration. Here we show that extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2 are activated in a mouse model of MFS, and both are inhibited by therapies directed against TGF β . Whereas selective inhibition of ERK1/2 activation ameliorated aortic growth, Smad4 deficiency exacerbated aortic disease and caused premature death in MFS mice. Smad4-deficient MFS mice uniquely showed activation of Jun N-terminal kinase-1 (JNK1), and a JNK antagonist ameliorated aortic growth in MFS mice that lacked or retained full Smad4 expression. Thus, noncanonical (Smad-independent) TGF β signaling is a prominent driver of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1 pathways is a potential therapeutic strategy for the disease.

The transforming growth factor- β (TGF β) ligands belong to a family of cytokines that regulates diverse cellular functions, including proliferation, differentiation, and synthetic repertoire. TGF β is secreted from cells as part of a large latent complex that binds to extracellular matrix (ECM) proteins including fibrillin-1 (1), the deficient gene product in Marfan syndrome (MFS). Current models posit that ECM sequestration of TGF β inhibits its activation, thereby limiting its ability to stimulate cell surface receptors, T β RI and T β RII (2, 3). In canonical

signaling, the T β RI/II complex phosphorylates receptor-activated Smad2 and/or Smad3 (to pSmad2 and pSmad3, respectively), which leads to recruitment of Smad4, translocation to the nucleus, and the transcription of Smad-dependent genes (4). Recent work has shown that TGF β also induces other (noncanonical) pathways, including the RhoA and mitogen-activated protein kinase (MAPK) cascades, the latter of which includes extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK), and p38 (5–7). TGF β activates these by phosphorylation to pERK, pJNK, and pp38, respectively. In light of these findings, the exclusive focus on Smad signaling in TGF β -related pathogenetic models needs to be reconsidered.

Increased Smad2/3 activation and increased expression of Smad-responsive genes (e.g., connective tissue growth factor and plasminogen-activator inhibitor-1, PAI-1) have been observed in the lung, skeletal muscle, mitral valve, and aortic wall in humans and a mouse model of MFS (8–11). Treatment of MFS mice with TGF β -neutralizing antibody (TGF β NAb) ameliorates the phenotype in all of these tissues, in association with attenuated pSmad2/3 signaling (8–11). A

similar rescue is achieved by using the angiotensin II type 1 receptor-blocker losartan (8–11), which is known to reduce the expression of TGF β ligands, receptors, and activators (12–14). It has also been shown that mutations in T β RI or II, which lead to a paradoxical increase in pSmad2 signaling in the aortic wall, cause Loeys-Dietz syndrome, a condition that has considerable phenotypic overlap with MFS, including aortic aneurysm (15, 16). Together, these earlier observations suggested that canonical TGF β signaling drives disease pathogenesis in MFS. We have now explored the relative contributions of canonical and noncanonical TGF β signaling cascades in MFS mice, by either genetically or pharmacologically inhibiting each cascade and analyzing the resultant phenotypic consequences.

We performed Western blot analysis on the proximal ascending aorta of 12-month-old mice heterozygous for a missense mutation in *Fbn1* (*Fbn1*^{C1039G/+}), a validated animal model of MFS (17). Compared with wild-type (WT) littermates, *Fbn1*^{C1039G/+} mice showed a significant increase in activation of Smad2, ERK1/2, and MAPK kinase 1 (MEK1), the upstream activator of ERK1/2 ($P < 0.05$, $P < 0.001$, and $P < 0.05$, respectively) (Fig. 1A). In contrast, there was no difference in the activation of Smad3; JNK1; p38; ERK5; Rho-associated coiled-coil containing protein kinase-1 (ROCK1); or LIMK1, a downstream target of ROCK1 (Fig. 1A and fig. S1) (18). Furthermore, an in vivo trial of fasudil, a well-established inhibitor of the RhoA/ROCK pathway [details discussed in (18)] failed to attenuate aortic root growth in *Fbn1*^{C1039G/+} mice (fig. S2).

Because TGF β NAb and losartan attenuate aortic root growth in *Fbn1*^{C1039G/+} mice (fig. S3) (10), if Smad2 or ERK1/2 are important mediators of aortic disease in MFS, one would expect their activation to be reduced by these agents. Prior work demonstrated that Smad2 activation is decreased by both therapies (10). We now find that compared with placebo-treated littermates, *Fbn1*^{C1039G/+} mice treated with either TGF β NAb or losartan also show a significant reduction in ERK1/2 activation ($P < 0.01$ for both) (Fig. 1B).

To confirm that ERK1/2 is a driver, rather than simply a marker, of aortic aneurysm progression, 2-month-old *Fbn1*^{C1039G/+} mice were treated for 2 months with the selective MEK1/2 inhibitor RDEA119 (19). Aortic root size was measured by echocardiography at 2 months (baseline before treatment) and 4 months of age (Fig.

¹Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ²Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ³Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ⁴Centre for Medical Genetics, Ghent University, 9000 Ghent, Belgium. ⁵National Institutes of Health Chemical Genomics Center, Rockville, MD 20850, USA. ⁶Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

*These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: hdietz@jhmi.edu.




Fig. 1. Canonical and noncanonical TGFβ signaling in the proximal ascending aorta. **(A)** Western blot analysis of 4 WT and *Fbn1*^{C1039G/+} mice. Note that only pSmad2, pERK1/2, and pMEK1 signaling are increased in *Fbn1*^{C1039G/+} mice. The graphs show normalization to β-actin, but the same outcomes were observed with normalization to the respective total proteins. **(B)** Western blot analysis of three each of WT and of *Fbn1*^{C1039G/+} mice treated with placebo, TGFβNAb, or losartan (Los). Note the significant reduction in pERK1/2 signaling after treatment with TGFβNAb (NAb) or losartan (Los). **(C)** Aortic root growth in placebo-treated WT (*n* = 5), placebo-treated *Fbn1*^{C1039G/+} (*n* = 6), RDEA119-treated WT (*n* = 3), and RDEA119-treated *Fbn1*^{C1039G/+} (*n* = 7) mice. Note that RDEA119 therapy selectively reduced growth in *Fbn1*^{C1039G/+} mice. Final absolute aortic root diameter (mm): WT (1.62 ± 0.08), placebo-treated *Fbn1*^{C1039G/+} (2.15 ± 0.17), RDEA119-treated WT (1.64 ± 0.09), RDEA119-treated *Fbn1*^{C1039G/+} (1.94 ± 0.07). **(D)** Western blot analysis of three placebo- and three RDEA119-treated *Fbn1*^{C1039G/+} mice, showing a selective reduction in pERK1/2 signaling in RDEA119-treated mice. Plac, placebo. Values are means ± 2 SEM. **P* < 0.05; ***P* < 0.01; †*P* < 0.001; NS, not significant.

IC). Aortic root growth was significantly greater in placebo-treated *Fbn1*^{C1039G/+} mice, compared with WT littermates (*P* < 0.05). Aortic root growth in RDEA119-treated *Fbn1*^{C1039G/+} mice was significantly less than that of placebo-treated *Fbn1*^{C1039G/+} littermates (*P* < 0.01) and indistinguishable from that observed in WT mice (*P* = 0.15). RDEA119 therapy had no significant effect in WT mice (*P* = 0.24), which illustrated that inhibition of ERK1/2 activation specifically targets MFS-associated pathological aortic root growth, while still allowing for normal physiological growth.

The specificity of RDEA119 was confirmed by Western blot analysis of the proximal ascending aorta. Compared with placebo-treated *Fbn1*^{C1039G/+} littermates, RDEA119-treated *Fbn1*^{C1039G/+} mice showed a significant reduction in ERK1/2 activation (*P* < 0.01), whereas Smad2, JNK1, p38 and ERK5 activation was unchanged (Fig. 1D). This result also shows that Smad2 activation in *Fbn1*^{C1039G/+} mice is not ERK-dependent. Together, these data suggest that TGFβ-driven ERK1/2 activation contributes to aortic aneurysm progression in MFS mice and that antagonism of this pathway may be therapeutically useful.

To determine whether canonical signaling contributes to aortic disease progression in MFS, we introduced haploinsufficiency for Smad4, a critical mediator of canonical TGFβ signaling, into our MFS mouse model. We bred *Fbn1*^{C1039G/+} mice to mice harboring a deletion of exon 8 of




Fig. 2. Effect of *Smad4* haploinsufficiency (*S4*^{+/-}) on aortic phenotype. **(A)** Survival curve of WT (*n* = 112), *S4*^{+/-} (*n* = 56), *Fbn1*^{C1039G/+} (*n* = 107) and *S4*^{+/-}:*Fbn1*^{C1039G/+} (*n* = 85) mice. Note the high rate of premature death due to aortic dissection in *S4*^{+/-}:*Fbn1*^{C1039G/+} mice. **(B)** Aortic root and ascending aortic diameter, measured by echocardiography, at 3 months of age in WT (*n* = 9), *S4*^{+/-} (*n* = 11), *Fbn1*^{C1039G/+} (*n* = 24), and *S4*^{+/-}:*Fbn1*^{C1039G/+} (*n* = 26) mice. Although *Fbn1*^{C1039G/+} mice showed a selective increase in aortic root diameter compared with WT littermates, *S4*^{+/-}:*Fbn1*^{C1039G/+} mice demonstrated an increase in both aortic root and ascending aortic diameter, compared with all other genotypes. **(C)** VVG staining of representative sections of the proximal ascending aorta. Compared with WT littermates, *Fbn1*^{C1039G/+} mice demonstrated medial thickening and elastic fiber fragmentation, both of which are exacerbated in *S4*^{+/-}:*Fbn1*^{C1039G/+} mice. Values are means ± 2 SEM. †*P* < 0.001; ††*P* < 0.0001; NS, not significant.

the *Smad4* gene. Homozygosity for this *Smad4* allele ($S4^{-/-}$) results in the death of embryos (20). In contrast, haploinsufficient mice ($S4^{+/-}$) are fertile, have normal life spans, and show clinically relevant attenuation of Smad-dependent signaling in several tissues, including the stomach, breast, and intestine (20).

The *Fbn1*^{C1039G/+} MFS mouse model shows progressive aortic root dilatation, but does not typically progress to aortic dissection or pre-

mature death. Whereas almost all WT, $S4^{+/-}$ and *Fbn1*^{C1039G/+} mice survived to 8 months of age, $S4^{+/-};Fbn1$ ^{C1039G/+} mice died prematurely. This was first evident by 1 month of age; by 3 months 40% had died, and by 8 months 70% had died (Fig. 2A). Necropsy of these animals revealed hemothorax and hemopericardium in all cases, indicative of proximal aortic rupture; there was no evidence of aortic rupture in any WT, $S4^{+/-}$, or *Fbn1*^{C1039G/+} mice.

Echocardiography at 3 months of age revealed significant enlargement of both the aortic root and the ascending aorta in $S4^{+/-};Fbn1$ ^{C1039G/+} mice, compared with *Fbn1*^{C1039G/+} littermates ($P < 0.0001$ and $P < 0.001$, respectively) (Fig. 2B). These data provide a conservative estimate of the effect of *Smad4* haploinsufficiency, because premature deaths in the $S4^{+/-};Fbn1$ ^{C1039G/+} cohort effectively eliminated more severe cases from the analysis. No difference in aortic root or ascending aortic size was observed between WT and $S4^{+/-}$ mice ($P = 0.20$ and $P = 0.20$, respectively) (Fig. 2B), which indicated that the deleterious effect of *Smad4* haploinsufficiency was limited to MFS.

After death of the mice, we performed Verhoeff–Van Gieson (VVG) staining of the proximal ascending aorta to assess whether there were any abnormalities in aortic architecture (Fig. 2C). Compared with WT littermates, *Fbn1*^{C1039G/+} mice showed increased aortic medial thickening, elastic fiber fragmentation, and elastic fiber disarray, collectively quantified as an aortic architecture score ($P < 0.0001$) (fig. S4). $S4^{+/-};Fbn1$ ^{C1039G/+} mice showed an exaggeration of these pathologic changes ($P < 0.05$). By contrast, there was no significant difference between WT and $S4^{+/-}$ mice ($P = 0.94$). The histological changes in the aorta therefore paralleled the echocardiography findings and support the conclusion that *Smad4* haploinsufficiency exacerbates aortic disease in MFS mice.

Using Western blot analysis, we evaluated the effect of *Smad4* haploinsufficiency on canonical and noncanonical TGF β signaling in the proximal ascending aorta (Fig. 3). As anticipated, $S4^{+/-}$ and $S4^{+/-};Fbn1$ ^{C1039G/+} mice showed a roughly 50% reduction in expression of Smad4 protein, compared with WT and *Fbn1*^{C1039G/+} mice. Compared with WT animals, *Fbn1*^{C1039G/+} mice showed significantly greater activation of Smad2 and ERK1/2 ($P < 0.01$ and $P < 0.05$, respectively) and a significant increase in expression of the Smad2-responsive gene product PAI-1 ($P < 0.01$). However, there was no further increase in Smad2 activation, ERK1/2 activation, or PAI-1 expression in $S4^{+/-};Fbn1$ ^{C1039G/+} mice ($P = 0.35$, $P = 0.90$, and $P = 0.85$, respectively). This indicates that *Smad4* haploinsufficiency did not attenuate Smad-dependent signaling and that increased Smad2 or ERK1/2 activation could not be invoked as the cause of the aortic disease exacerbation seen in $S4^{+/-};Fbn1$ ^{C1039G/+} mice.

We next assessed whether other TGF β -dependent canonical or noncanonical pathways could account for these changes (Fig. 3). There was no significant difference in Smad3 or p38 activation in WT, *Fbn1*^{C1039G/+}, or $S4^{+/-};Fbn1$ ^{C1039G/+} mice. Although there was no significant difference in JNK1 activation between *Fbn1*^{C1039G/+} and WT mice, $S4^{+/-};Fbn1$ ^{C1039G/+} mice demonstrated unique activation of JNK1 ($P < 0.05$). We therefore treated a cohort of $S4^{+/-};Fbn1$ ^{C1039G/+} mice with SP600125, a selective JNK inhibitor (21). SP600125 treatment led to a significant re-




Fig. 3. Effect of *Smad4* haploinsufficiency ($S4^{+/-}$) on aortic signaling. Western blot analysis of the proximal ascending aorta in three mice each: WT, $S4^{+/-}$, *Fbn1*^{C1039G/+}, and $S4^{+/-};Fbn1$ ^{C1039G/+}. Note the unique activation of JNK1 in $S4^{+/-};Fbn1$ ^{C1039G/+} mice compared with all other genotypes. Values are means \pm 2 SEM. * $P < 0.05$; ** $P < 0.01$; NS, not significant.




Fig. 4. Effect of JNK antagonism in the presence of SP600125. (A) Aortic root and ascending aortic growth, as measured by echocardiography, in WT mice ($n = 6$) and *Fbn1*^{C1039G/+} placebo- ($n = 5$) or SP600125-treated ($n = 5$) mice, as well as placebo- ($n = 8$) or SP600125-treated ($n = 11$) $S4^{+/-};Fbn1$ ^{C1039G/+} littermates. Note that JNK inhibition decreased aortic root growth in $S4^{+/-};Fbn1$ ^{C1039G/+} and *Fbn1*^{C1039G/+} mice and reduced ascending aortic growth in $S4^{+/-};Fbn1$ ^{C1039G/+} mice. Final absolute aortic root and ascending aortic diameter (mm): WT (1.66 ± 0.06 ; 1.33 ± 0.06), placebo- (2.31 ± 0.02 ; 1.43 ± 0.10) or SP600125-treated (1.97 ± 0.16 ; 1.38 ± 0.06) *Fbn1*^{C1039G/+} mice, placebo- (2.33 ± 0.38 ; 1.85 ± 0.37) or SP600125-treated (2.09 ± 0.16 ; 1.47 ± 0.14) $S4^{+/-};Fbn1$ ^{C1039G/+} mice. (B) Survival curve for $S4^{+/-};Fbn1$ ^{C1039G/+} mice treated with either placebo ($n = 8$) or SP600125 ($n = 11$), showing prevention of premature death in SP600125-treated animals. JNKi, JNK inhibitor SP600125; Plac, placebo. Values are means \pm 2 SEM. * $P < 0.05$; ** $P < 0.01$; † $P < 0.001$; †† $P < 0.0001$; NS, not significant.

duction in both aortic root and ascending aortic growth in $S4^{+/-};Fbn1^{C1039G/+}$ mice, compared with placebo-treated littermates ($P < 0.001$ and $P < 0.05$, respectively) (Fig. 4A). Furthermore, SP600125 treatment prevented the premature death due to aortic dissection seen in these animals. At 3 months of age, 50% of placebo-treated $S4^{+/-};Fbn1^{C1039G/+}$ mice had died from aortic dissection, whereas all of the SP600125-treated $S4^{+/-};Fbn1^{C1039G/+}$ mice were still alive (Fig. 4B).

Although JNK1 activation is not increased in the aortas of $Fbn1^{C1039G/+}$ mice, SP600125 treatment ameliorated their aortic root growth, compared with placebo-treated $Fbn1^{C1039G/+}$ littermates ($P < 0.05$) (Fig. 4A). This correlated with a reduction of JNK1 activation to levels below baseline, whereas ERK1/2 activation remained unaffected, in SP600125-treated $Fbn1^{C1039G/+}$ animals (fig. S5). This observation is consistent with prior work showing that SP600125 can ameliorate abdominal aortic aneurysm induced by the periaortic application of calcium chloride, in association with reduced JNK1 activation (22). These data suggest that both ERK1/2 and JNK1 can contribute to aortic disease in fibrillin-1-deficient mice; whether or not this relies upon downstream cross-talk between these signaling cascades remains to be determined. Taken together, these data further support the conclusion that noncanonical TGF β signaling is a prominent determinant of aortic aneurysm progression in MFS mice.

ERK activation was recently shown to occur in the aorta of a fibulin-4-deficient mouse model of cutis laxa with aneurysm, although a mechanistic link remains to be elucidated (23). ERK

activation also appears to be central to the pathogenesis of cardiovascular disease in Noonan syndrome (24, 25). Although aortic aneurysm has been described in this condition (26, 27), it is not highly penetrant, which suggests as yet undefined context specificity. It is also notable that the combination of aortic root and ascending aortic aneurysm seen in $S4^{+/-};Fbn1^{C1039G/+}$ mice is similar to that observed in individuals with either Loeys-Dietz syndrome or bicuspid aortic valve and aneurysm. Both conditions are associated with increased TGF β signaling in the aortic wall (15, 28), but the contribution of non-canonical TGF β signaling cascades has not been revealed.

In summary, this work defines a critical role for noncanonical TGF β -dependent signaling in aneurysm pathogenesis in MFS mice. It also defines inhibition of ERK1/2 or JNK1 activation as possible therapeutic strategies for MFS and suggests that such therapies may find broader application. Finally, it focuses attention on non-canonical TGF β signaling cascades in MFS-related conditions, where etiology or pathogenesis remains poorly understood.

References and Notes

- Z. Isogai *et al.*, *J. Biol. Chem.* **278**, 2750 (2003).
- H. C. Dietz, *J. Clin. Invest.* **120**, 403 (2010).
- R. O. Hynes, *Science* **326**, 1216 (2009).
- J. S. Kang, C. Liu, R. Derynck, *Trends Cell Biol.* **19**, 385 (2009).
- R. Derynck, Y. E. Zhang, *Nature* **425**, 577 (2003).
- M. K. Lee *et al.*, *EMBO J.* **26**, 3957 (2007).
- M. Yamashita *et al.*, *Mol. Cell* **31**, 918 (2008).
- E. R. Neptune *et al.*, *Nat. Genet.* **33**, 407 (2003).
- C. M. Ng *et al.*, *J. Clin. Invest.* **114**, 1586 (2004).
- J. P. Habashi *et al.*, *Science* **312**, 117 (2006).
- R. D. Cohn *et al.*, *Nat. Med.* **13**, 204 (2007).

- G. Wolf, F. N. Ziyadeh, R. A. Stahl, *J. Mol. Med.* **77**, 556 (1999).
- N. Fukuda *et al.*, *Am. J. Hypertens.* **13**, 191 (2000).
- T. Naito *et al.*, *Am. J. Physiol. Renal Physiol.* **286**, F278 (2004).
- B. L. Loeys *et al.*, *Nat. Genet.* **37**, 275 (2005).
- B. L. Loeys *et al.*, *N. Engl. J. Med.* **355**, 788 (2006).
- D. P. Judge *et al.*, *J. Clin. Invest.* **114**, 172 (2004).
- Materials and methods are available as supporting material on Science Online.
- C. Iverson *et al.*, *Cancer Res.* **69**, 6839 (2009).
- X. Xu *et al.*, *Oncogene* **19**, 1868 (2000).
- B. L. Bennett *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **98**, 13681 (2001).
- K. Yoshimura *et al.*, *Nat. Med.* **11**, 1330 (2005).
- J. Huang *et al.*, *Circ. Res.* **106**, 583 (2010).
- T. Araki *et al.*, *Nat. Med.* **10**, 849 (2004).
- T. Nakamura *et al.*, *J. Clin. Invest.* **117**, 2123 (2007).
- J. M. Morgan, M. O. Coupe, M. Honey, G. A. Miller, *Eur. Heart J.* **10**, 190 (1989).
- R. Purnell, I. Williams, U. Von Oppell, A. Wood, *Eur. J. Cardiothorac. Surg.* **28**, 346 (2005).
- D. Gomez *et al.*, *J. Pathol.* **218**, 131 (2009).
- Supported by the National Institutes of Health (H.C.D. and D.P.J.), Howard Hughes Medical Institute (H.C.D.), National Marfan Foundation (H.C.D., J.P.H., and J.J.D.), Cellular and Molecular Medicine Training Program (J.J.D.), National Human Genome Research Institute Intramural Research Program and the NIH Therapeutics for Rare and Neglected Diseases Program (C.J.T., S.P., and J.J.M.), and the Smilow Center for Marfan Syndrome Research (H.C.D.). We thank Dr. C. Deng for the *Smad4*-targeted mice. Johns Hopkins University and the authors (H.C.D., J.P.H., D.P.J., and R.C.) have filed a patent relating to the use of TGF β antagonists, including angiotensin II type 1 receptor blockers, for the treatment of Marfan syndrome.

Supporting Online Material

www.sciencemag.org/cgi/content/full/332/6027/358/DC1
Materials and Methods
Figs. S1 to S7
References

11 May 2010; accepted 4 March 2011
10.1126/science.1192149

Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism

Jennifer P. Habashi,^{1,2*} Jefferson J. Doyle,^{1*} Tammy M. Holm,¹ Hamza Aziz,¹ Florian Schoenhoff,¹ Djahida Bedja,³ YiChun Chen,¹ Alexandra N. Modiri,¹ Daniel P. Judge,⁴ Harry C. Dietz^{1,2,4†}

Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown. We show that loss of AT2 expression accelerates the aberrant growth and rupture of the aorta in a mouse model of Marfan syndrome (MFS). The selective AT1 receptor blocker (ARB) losartan abrogated aneurysm progression in the mice; full protection required intact AT2 signaling. The angiotensin-converting enzyme inhibitor (ACEi) enalapril, which limits signaling through both receptors, was less effective. Both drugs attenuated canonical transforming growth factor- β (TGF β) signaling in the aorta, but losartan uniquely inhibited TGF β -mediated activation of extracellular signal-regulated kinase (ERK), by allowing continued signaling through AT2. These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in MFS and related disorders.

Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that includes a predisposition for aortic root aneurysm and aortic rupture. MFS is caused

by a deficiency of the microfibrillar constituent protein fibrillin-1 that is imposed by heterozygous mutations in *FBN1*. In prior work, we demonstrated that transforming growth factor- β

(TGF β) signaling was elevated in affected tissues of mice heterozygous for a cysteine substitution in an epidermal growth factor-like domain of fibrillin-1 ($Fbn1^{C1039G/+}$), the most common class of mutation in people with MFS (1–4). Many disease manifestations—including aortic aneurysm (1), developmental emphysema (2), myxomatous degeneration of the atrioventricular valves (3), and skeletal muscle myopathy (4)—are attenuated by systemic administration of a pan-specific polyclonal TGF β -neutralizing antibody (TGF β NAb) in fibrillin-1-deficient mice. Similar protection was achieved by treating $Fbn1^{C1039G/+}$ mice with the angiotensin II (AngII) type 1 (AT1) receptor blocker (ARB) losartan (1, 4). ARBs can attenuate

¹Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ²Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ³Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ⁴Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

*These authors contributed equally to this work.

†To whom correspondence should be addressed. E-mail: hdietz@jhmi.edu